Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
Sponsor: AbbVie
Summary
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
Official title: A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
73
Start Date
2025-01-22
Completion Date
2026-04
Last Updated
2026-02-17
Healthy Volunteers
Yes
Conditions
Interventions
ABBV-142
Intravenous (IV) Infusion
ABBV-142
Subcutaneous (SC) Injection
Placebo
IV Infusion
Placebo
SC Injection
Locations (1)
Acpru /Id# 271899
Grayslake, Illinois, United States